G Protein News and Research

RSS

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.

5 Jun 2012

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Senesco Technologies, Inc. reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

5 Jun 2012

Researchers uncover brain signaling pathway responsible for renal excretory function

Boston University School of Medicine (BUSM) researchers recently uncovered a brain signaling pathway responsible for regulating the renal excretion of sodium. The findings appear in the Journal of the Federation of American Societies for Experimental Biology.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.

5 Jun 2012

MARIJUANA announces corporate name change to Hemp

MARIJUANA, INC. is proud to announce a corporate name change to Hemp, Inc. The change goes into effect immediately.

4 Jun 2012

NIH awards $1.9M grant to study genetic control of cell migration

Developmental biologists Dominique Alfandari and Hélène Cousin at the University of Massachusetts Amherst recently received a five-year, $1.9 million grant from the U.S. National Institutes of Health to investigate craniofacial development in a frog model to better understand genetic control of cell migration.

2 Jun 2012

Engineered proteins demonstrate flu-fighting potency

Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.

2 Jun 2012

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

Walnuts make a nutritious snack

Ninety percent of American adults snack daily and could be gaining valuable nutrition. A paper published in the British Journal of Nutrition found that smaller nutritious meals eaten throughout the day contribute significantly to the nutrient quality of the diet. The key is making snacking choices that are not "empty calories" but healthful options, providing important vitamins and minerals.

2 Jun 2012

GPR21 inhibitors may hold promise for diabetes

In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into other tissues. Obesity is a major factor that contributes to insulin resistance, which can eventually lead to type 2 diabetes. Previous studies have shown that proinflammatory molecules found in fat tissue decreases sensitivity of tissues to insulin.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.

2 Jun 2012

UH CNRCS students achieve significant milestones in cancer therapy research

Four University of Houston (UH) students are well on their way to emerging cancer research careers upon achieving significant milestones this spring in their work toward new therapies for prostate and breast cancer.

2 Jun 2012

Exercise reduces expression of cytokines and alleviates neuropathic pain

Exercise helps to alleviate pain related to nerve damage (neuropathic pain) by reducing levels of certain inflammation-promoting factors, suggests an experimental study in the June issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jun 2012

First study to correlate dietary fiber intake with inflammatory markers in adolescents

Adolescents who don't eat enough fiber tend to have bigger bellies and higher levels of inflammatory factors in their blood, both major risk factors for cardiovascular disease and diabetes, researchers report.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

Amarantus to announce results from preclinical study of new protein therapy for TBI

Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp., announced today that its latest joint venture target, Amarantus BioSciences, Inc., expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).

2 Jun 2012

G Protein News and Research

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Alnylam announces results from ALN-VSP Phase I study on liver cancers

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Researchers uncover brain signaling pathway responsible for renal excretory function

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

MARIJUANA announces corporate name change to Hemp

NIH awards $1.9M grant to study genetic control of cell migration

Engineered proteins demonstrate flu-fighting potency

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Walnuts make a nutritious snack

GPR21 inhibitors may hold promise for diabetes

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

UH CNRCS students achieve significant milestones in cancer therapy research

Exercise reduces expression of cytokines and alleviates neuropathic pain

First study to correlate dietary fiber intake with inflammatory markers in adolescents

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Amarantus to announce results from preclinical study of new protein therapy for TBI

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News